期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

白细胞介素-18修饰的树突状细胞瘤苗的制备及其抗肿瘤免疫保护作用的研究 被引量：1

白细胞介素-18修饰的树突状细胞瘤苗的制备及其抗肿瘤免疫保护作用的研究
下载PDF
导出
摘要 目的研究树突状细胞(DC)瘤苗的抗肿瘤免疫保护治疗作用,进一步探索DC为基础的肿瘤免疫治疗的新途径。方法以腺病毒为载体转染IL-18和/或gp100-DC,制备DC瘤苗,以ELISA、RT-PCR、FACS及混合淋巴细胞反应(MLR)检测所制备的DC瘤苗的效果,以黑色素肿瘤动物模型鉴定DC瘤苗的抗肿瘤免疫保护作用。结果本研究成功制备了DC瘤苗,IL-18/gp100-DC的抗肿瘤免疫保护作用明显强于IL-18-DC或gp100-DC瘤苗。结论Th1型细胞因子IL-18和gp100共转染能显著增强DC的抗肿瘤作用。 Objective To explore the anti - tumor effect of dendritic cells （DC） vaccine and new immunotherapy method. Methods Cytokine interleukin - 18 （IL- 18） an melanoma- associated antigen gpl00 were transfectod into bone marrow- derived DC （IL- 18/gp100- DC）, which were used as vaccine to induce the protective in a B16 melanoma model. And the effect of DC vaccine were detected through ELISA, RT - PCR, FACS and MLR. Results DC vaccines were successful constructed. The effect of anti - tumor immunity in IL - 18/gp100 - DC was significant higher than that of IL - 18 - DC or gp100 - DC. Conclusion The effect of anati - tumor was significanly enhanced with DC vaccine co - expressing Th1 cytokine IL- 18 and gp100.
作者 王峻 何炳荣 孙宏高 邵传森 沈建根
机构地区 杭州市红十字会医院 浙江大学免疫学研究所
出处 《浙江临床医学》 2006年第1期5-6,共2页 Zhejiang Clinical Medical Journal
关键词 树突状细胞瘤苗 免疫保护作用 抗肿瘤免疫 白细胞介素-18 制备 混合淋巴细胞反应 TH1型细胞因子 IL-18 DC瘤苗 Dendritic Cells Vaccine Interleukin - 18 Gene therapy Anti - tumor immunity
分类号 R73-36 [医药卫生—肿瘤]
  • 相关文献

参考文献12

  • 1Steinman RM.The dendritic cell system and its role in immunogenicity.Annu Rev Immunol,1991,9:271-296.
  • 2Bubenik J.Genetically engineered dendritic cell-based cancer vaccines.Int J Oncol,2001,18:475-478.
  • 3Schreurs MW,Eggert AA,de Boer AJ,et al.Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model.Cancer Res,2000,60:6995-7001.
  • 4Pecher G,Spahn G,Schirrmann T,et al.Mucin gene (MUC1) transfer into human dendritic cells by cationic liposomes and recombinant adenovirus.Anticancer Res,2001,21:2591-2596.
  • 5Kirk CJ,Mule JJ.Gene modified dendritic cells for use in tumor vaccines.Hum Gene Ther,2000,11:797-806.
  • 6Nishimura T,Iwakabe K,Sekimoto M,et al.Distinct role of antigen-specific T helper type 1 Th1 and Th2 cells in tumor eradication in vivo.J Exp Med,1999,190:617-627.
  • 7Smeltz RB,Chen J,Hu LJ,et al.Regulation of interleukin (IL)-18 receptor alpha chain expression on CD4(+) T cells during T helper (Th)1/Th2 differentiation Critical downregulatory role of IL-4.J Exp Med,2001,194:143-153.
  • 8Tatsumi T,Gambotto A,Robbins PD,et al.Interleukin 18 gene transfer expands the repertoire of antitumor Th1 type immunity elicited by dendritic cell based vaccines in association with enhanced therapeutic efficacy.Cancer Res,2002,62:5853-5858.
  • 9Whiteside TL,Odoux C.Dendritic cell biology and cancer therapy.Cancer Immunol Immunother,2004,53(3):240-248.
  • 10Conrad C,Nestle FO.Dendritic cell based cancer therapy.Curr Opin Mol Ther,2003,5(4):405-412.

同被引文献8

  • 1Murphy C,Tioa B,Ragde H,et al.Phase I clinical trial:T-cell therapy for praelate cancer using autologous dandritic cells pulsed with HLA-A0201-specific peptides from prosteta-specific ns,membrane antigen[J].Prostate,1996,29:371 ～ 380.
  • 2Nestle F0,Aligagic S,Gilliet M,et al.Vaccination of melanoma patients with peptide or tumor lysate-pulsed dendritic cells[J].Nat Med,1998,4:328 ～ 332.
  • 3Gong J,Avigen D,Chen D,et al.Activetion of antitumor cytotaxic Tlymphocytes by fusions of human denditic cells and breest catcinoma cell[J].Proc Natl Acad Sci USA,2000,97;2715 ～ 2718.
  • 4Kugler A,Stuhler G,Walden P,"L Regnession d human mets-static rant call cucin-rafter vaccirution with tumor celldendritic.bybrids[J].Nst Med,2000,6:332 ～ 336.
  • 5Paglia P,Chiodoni C,Rodolfo M,et al.Murine dendritic cells loeded in vitro with soluble protein prime cytotoxic Tlymphocytes against tumor antigen in vivo[J].J Exp Med,1996,1883;317～322.
  • 6Thomas R,Chambers M,BoytarR,et al.Metastatic lesions in the joint associated with acute inflammatoryarthritis after dendritic cell immunotherapy for metastatic melanoma[J].Cancer Immunol Immunother,1999,48(2-3):118 ～ 122.
  • 7Siders W M,Vergilis K L,Johnson C,et al.Induction of specific antitumor immunity in the mouse with the electrofusionproductof tumor cells and dendritic cells[J].Mol Ther,2003,7:498～ 505.
  • 8Fong L,Brockstedt D,Benike C,et al.Dendrfitic cells injected via different routes induce immunity in cancer patients[J].J Immunology,2002,41:249 ～ 257.

引证文献1

二级引证文献4

浙江临床医学
2006年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部